Marco Agostini

List of Publications by Year in Descending Order

125 papers	2,544 citations	29 h-index	43 g-index
148 ext. papers	3,068 ext. citations	4.9 avg, IF	4.93 L-index

#	Paper	IF	Citations
125	An investigation on [5 fluorouracil and epigallocatechin-3-gallate] complex activity on HT-29 cell death and its stability in gastrointestinal fluid.. *Oncotarget*, **2022**, 13, 476-489	3.3	0
124	A method for assessing plasma free fatty acids from C2 to C18 and its application for the early detection of colorectal cancer.. *Journal of Pharmaceutical and Biomedical Analysis*, **2022**, 215, 114762	3.5	1
123	Decellularized normal and cancer tissues as tools for cancer research. *Cancer Gene Therapy*, **2021**,	5.4	3
122	Tumor Cells and the Extracellular Matrix Dictate the Pro-Tumoral Profile of Macrophages in CRC. *Cancers*, **2021**, 13,	6.6	1
121	A rhabdomyosarcoma hydrogel model to unveil cell-extracellular matrix interactions. *Biomaterials Science*, **2021**,	7.4	1
120	Integration of Flexibility from Distributed Energy Resources: Mapping the Innovative Italian Pilot Project UVAM. *Energies*, **2021**, 14, 1910	3.1	7
119	An electrospray ionization study on complexes of amylin with Cu(II) and Cu(I). *Journal of Mass Spectrometry*, **2021**, 56, e4773	2.2	
118	Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?. *Diagnostics*, **2021**, 11,	3.8	1
117	Mass spectrometry in the study of molecular complexes between 5-fluorouracil and catechins. *Journal of Mass Spectrometry*, **2021**, 56, e4682	2.2	3
116	Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. *Frontiers in Oncology*, **2020**, 10, 583228	5.3	2
115	Recellularized Colorectal Cancer Patient-derived Scaffolds as in vitro Pre-clinical 3D Model for Drug Screening. *Cancers*, **2020**, 12,	6.6	17
114	Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are. *Frontiers in Oncology*, **2020**, 10, 76	5.3	9
113	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. *Pathology Research and Practice*, **2020**, 216, 152907	3.4	9
112	miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer. *British Journal of Cancer*, **2020**, 122, 1354-1366	8.7	20
111	Leveraging Demand Flexibility by Exploiting Prosumer Response to Price Signals in Microgrids. *Energies*, **2020**, 13, 3078	3.1	5
110	Patient-Derived Scaffolds of Colorectal Cancer Metastases as an Organotypic 3D Model of the Liver Metastatic Microenvironment. *Cancers*, **2020**, 12,	6.6	24
109	MASS SPECTROMETRY FOR A HOLISTIC VIEW OF NATURAL EXTRACTS OF PHYTOTHERAPEUTIC INTEREST. *Mass Spectrometry Reviews*, **2020**, 39, 553-573	11	0

108	Circulating Biomarkers for Response Prediction of Rectal Cancer to Neoadjuvant Chemoradiotherapy. *Current Medicinal Chemistry*, **2020**, 27, 4274-4294	4.3	4
107	Evidence of noncovalent complexes in some natural extracts: Ceylon tea and mate extracts. *Journal of Mass Spectrometry*, **2020**, 55, e4459	2.2	2
106	Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment. *Frontiers in Oncology*, **2020**, 10, 1122	5.3	12
105	Voltammetric responses at modified electrodes and aggregation effects of two anticancer molecules: irinotecan and sunitinib. *New Journal of Chemistry*, **2020**, 44, 18233-18241	3.6	0
104	BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. *Journal of Pathology*, **2020**, 250, 134-147	9.4	15
103	Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of "Stealthy" Nanomaterials. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 166	5.8	92
102	Nanovectors Design for Theranostic Applications in Colorectal Cancer. *Journal of Oncology*, **2019**, 2019, 2740923	4.5	19
101	Ancillary services provision by aggregators and impact on distribution network operation **2019**,		1
100	Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients. *International Journal of Tryptophan Research*, **2019**, 12, 1178646919890293	5.6	2
99	New Mass Spectrometric Approaches for the Quantitative Evaluation of Anticancer Drug Levels in Treated Patients. *Therapeutic Drug Monitoring*, **2019**, 41, 1-10	3.2	5
98	The role of mass spectrometry in studies of glycation processes and diabetes management. *Mass Spectrometry Reviews*, **2019**, 38, 112-146	11	11
97	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. *Translational Oncology*, **2019**, 12, 282-291	4.9	10
96	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. *Nature Genetics*, **2018**, 50, 219-228	36.3	71
95	miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. *Journal of Clinical Pathology*, **2018**, 71, 344-350	3.9	23
94	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. *Journal of Controlled Release*, **2018**, 281, 1-10	11.7	18
93	Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 160, 360-367	3.5	16
92	Diagnostic Devices for Circulating Biomarkers Detection and Quantification. *Current Medicinal Chemistry*, **2018**, 25, 4304-4327	4.3	3
91	Preclinical three-dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation. *Journal of Cellular Physiology*, **2018**, 234, 181-191	7	16

90	Decellularized colorectal cancer matrix as bioactive microenvironment for in vitro 3D cancer research. *Journal of Cellular Physiology*, **2018**, 233, 5937-5948	7	43
89	Inflammation and Cancer: In Medio Stat Nano. *Current Medicinal Chemistry*, **2018**, 25, 4208-4223	4.3	16
88	Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts. *Metabolites*, **2018**, 8,	5.6	4
87	Experimental Evidence of the Presence of Bimolecular Caffeine/Catechin Complexes in Green Tea Extracts. *Journal of Natural Products*, **2018**, 81, 2338-2347	4.9	8
86	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. *Cancer Cell International*, **2018**, 18, 131	6.4	6
85	Long non-coding RNA and extracellular matrix: the hidden players in cancer-stroma cross-talk. *Non-coding RNA Research*, **2018**, 3, 174-177	6	20
84	Mass spectrometry in the pharmacokinetic studies of anticancer natural products. *Mass Spectrometry Reviews*, **2017**, 36, 213-251	11	16
83	Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy. *Journal of Cellular Physiology*, **2017**, 232, 426-435	7	31
82	Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. *Digestive and Liver Disease*, **2017**, 49, 630-638	3.3	7
81	Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy. *Journal of Controlled Release*, **2017**, 248, 144-152	11.7	41
80	Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. *Journal of Mass Spectrometry*, **2017**, 52, 283-289	2.2	4
79	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. *EBioMedicine*, **2017**, 20, 39-49	8.8	112
78	Medium chain fatty acids in intrauterine growth restricted and small for gestational age pregnancies. *Metabolomics*, **2017**, 13, 1	4.7	5
77	Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. *International Journal of Cancer*, **2017**, 140, 1888-1898	7.5	62
76	Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms. *Tumor Biology*, **2017**, 39, 1010428317728683	2.9	6
75	Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases. *Nanoscale*, **2017**, 9, 14581-14591	7.7	41
74	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. *Histopathology*, **2017**, 71, 1008-1011	7.3	8
73	Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. *Metabolomics*, **2017**, 13, 1	4.7	16

72	Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior?. *Journal of Cellular Physiology*, **2017**, 232, 967-975	7	84
71	SerpinB3 upregulates the Cyclooxygenase-2 / Catenin positive loop in colorectal cancer. *Oncotarget*, **2017**, 8, 15732-15743	3.3	6
70	Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. *PLoS ONE*, **2017**, 12, e0169454	3.7	21
69	Peptide Patterns as Discriminating Biomarkers in Plasma of Patients With Familial Adenomatous Polyposis. *Clinical Colorectal Cancer*, **2016**, 15, e75-92	3.8	6
68	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. *Oncotarget*, **2016**, 7, 19781-93	3.3	11
67	Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. *Oncotarget*, **2016**, 7, 28647-57	3.3	48
66	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	10
65	Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 6321-8	4.4	26
64	Alterations of the Plasma Peptidome Profiling in Colorectal Cancer Progression. *Journal of Cellular Physiology*, **2016**, 231, 915-25	7	12
63	miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. *Journal of Clinical Pathology*, **2016**, 69, 415-21	3.9	11
62	p65BTK targeting restores the apoptotic response to chemotherapy of p53-null drug-resistant colon cancer cells. *European Journal of Cancer*, **2016**, 69, S140	7.5	3
61	Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma. *European Journal of Mass Spectrometry*, **2016**, 22, 217-228	1.1	3
60	Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 5369-77	4.4	7
59	Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers. *Nanomedicine*, **2015**, 10, 1923-40	5.6	52
58	A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. *Cancer Biology and Therapy*, **2015**, 16, 1160-71	4.6	30
57	Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy. *Journal of Cellular Physiology*, **2015**, 230, 1822-8	7	13
56	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. *Hereditary Cancer in Clinical Practice*, **2015**, 13, 18	2.3	26
55	An Advanced Lithium-Ion Sulfur Battery for High Energy Storage. *Advanced Energy Materials*, **2015**, 5, 1500481	21.8	84

54	The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: preliminary results. *Journal of Mass Spectrometry*, **2015**, 50, 959-62	2.2	4
53	An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. *Oncotarget*, **2015**, 6, 32561-74	3.3	32
52	Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. *International Journal of Biological Markers*, **2015**, 30, e136-41	2.8	32
51	MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis. *Current Drug Targets*, **2015**, 16, 383-92	3	17
50	Biomarker Signature Discovery from Mass Spectrometry Data. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2014**, 11, 766-72	3	6
49	NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells. *Cancer Research*, **2014**, 74, 2106-18	10.1	46
48	Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. *European Journal of Mass Spectrometry*, **2014**, 20, 445-59	1.1	6
47	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. *Oncotarget*, **2014**, 5, 6611-9	3.3	49
46	Predictive response biomarkers in rectal cancer neoadjuvant treatment. *Frontiers in Bioscience - Scholar*, **2014**, 6, 110-9	2.4	21
45	Factors affecting the treatment of multiple colorectal adenomas. *Surgical Endoscopy and Other Interventional Techniques*, **2013**, 27, 207-13	5.2	4
44	Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. *Biomedicine and Pharmacotherapy*, **2013**, 67, 723-30	7.5	43
43	A prognostic role for Nm23-H1 in laryngeal carcinoma treated with postoperative radiotherapy: an introductory investigation. *European Archives of Oto-Rhino-Laryngology*, **2013**, 270, 197-203	3.5	4
42	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. *Techniques in Coloproctology*, **2013**, 17, 79-87	2.9	10
41	MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis. *International Journal of Cancer*, **2013**, 132, 1060-9	7.5	12
40	Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. *British Journal of Cancer*, **2013**, 108, 278-84	8.7	51
39	High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. *Annals of Surgery*, **2013**, 257, 900-4	7.8	21
38	Multivariate Analysis Approach to the Serum Peptide Profile of Morbidly Obese Patients. *Disease Markers*, **2013**, 34, 269-278	3.2	
37	Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. *Annals of Surgical Oncology*, **2012**, 19, 3089-96	3.1	54

36	Serum seleno-proteins status for colorectal cancer screening explored by data mining techniques - a multidisciplinary pilot study. *Microchemical Journal*, **2012**, 105, 124-132	4.8	14
35	Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. *Clinical Colorectal Cancer*, **2012**, 11, 268-74	3.8	5
34	Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis. *Molecular Biology Reports*, **2012**, 39, 9307-10	2.8	9
33	PKH26 staining defines distinct subsets of normal human colon epithelial cells at different maturation stages. *PLoS ONE*, **2012**, 7, e43379	3.7	9
32	Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy. *Tumor Biology*, **2012**, 33, 857-64	2.9	2
31	Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. *Histopathology*, **2012**, 61, 247-56	7.3	18
30	Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. *Cancer Biomarkers*, **2012**, 11, 89-98	3.8	57
29	APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation. *International Journal of Biological Markers*, **2012**, 27, 13-9	2.8	4
28	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. *Pharmacogenomics Journal*, **2011**, 11, 214-26	3.5	54
27	Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. *Annals of Surgical Oncology*, **2011**, 18, 2461-8	3.1	87
26	Integrated analysis of unclassified variants in mismatch repair genes. *Genetics in Medicine*, **2011**, 13, 115-24	2.4	31
25	A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. *Cancer Biomarkers*, **2010**, 6, 49-61	3.8	19
24	miRNAs in colon and rectal cancer: A consensus for their true clinical value. *Clinica Chimica Acta*, **2010**, 411, 1181-6	6.2	35
23	Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. *Diseases of the Colon and Rectum*, **2010**, 53, 1670-5	3.1	9
22	Evaluation of Cell-free DNA in Urine as a Marker for Bladder Cancer Diagnosis. *International Journal of Biological Markers*, **2009**, 24, 147-155	2.8	17
21	MALDI-MS-NIST library approach for colorectal cancer diagnosis. *Rapid Communications in Mass Spectrometry*, **2009**, 23, 2839-45	2.2	11
20	Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. *International Journal of Biological Markers*, **2009**, 24, 147-55	2.8	18
19	Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. *Drugs and Aging*, **2008**, 25, 531-9	4.7	11

18	The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. *Cancer Letters*, **2008**, 268, 308-13	9.9	23
17	Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. *Clinical Cancer Research*, **2008**, 14, 7444-51	12.9	76
16	Proximal colon cancer in patients aged 51-60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines. *International Journal of Colorectal Disease*, **2008**, 23, 801-6	3	13
15	An investigation on the nature of the peptide at m/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis. *Journal of Mass Spectrometry*, **2007**, 42, 1606-12	2.2	6
14	Reply to Jaskowski et al. *European Journal of Human Genetics*, **2007**, 15, 141-142	5.3	2
13	Long-term follow-up after endoscopic forceps biopsies for early stage duodenal carcinoid: case report and review of endoscopic treatments. *Endoscopy*, **2007**, 39 Suppl 1, E128	3.4	4
12	Determining therapeutic approaches in the elderly with rectal cancer. *Drugs and Aging*, **2007**, 24, 781-90	4.7	7
11	Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. *Journal of Mass Spectrometry*, **2006**, 41, 1546-53	2.2	22
10	A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. *Pharmacogenetics and Genomics*, **2006**, 16, 817-24	1.9	51
9	Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. *European Journal of Human Genetics*, **2006**, 14, 63-8	5.3	35
8	Rectal cancer neoadjuvant treatment in elderly patients. *Anticancer Research*, **2006**, 26, 3913-23	2.3	22
7	Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. *Journal of Mass Spectrometry*, **2005**, 40, 123-6	2.2	12
6	Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. *American Journal of Gastroenterology*, **2005**, 100, 1886-91	0.7	56
5	Neoadjuvant treatment for locally advanced rectal carcinoma. *Critical Reviews in Oncology/Hematology*, **2004**, 52, 61-71	7	10
4	Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients. *International Journal of Biological Markers*, **2004**, 19, 332-6	2.8	3
3	Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer. *Diseases of the Colon and Rectum*, **2003**, 46, 305-12	3.1	20
2	Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L1189-99	5.8	27
1	Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management. *Advanced Therapeutics*,2100152	4.9	0